Will Zentiva find itself in bidding war?; GSK plant workers expect layoffs;

> With a shareholder meeting coming up July 9, will dueling offers for Czech generics firm Zentiva turn into a bidding war between Sanofi-Aventis and PPF? Report

> GlaxoSmithKline workers at a plant in Scotland have been warned to expect layoffs after a review of its operations is complete; no word yet on how many might lose their jobs. Report

> Biovail founder Eugene Melnyk may be trying to put a positive spin on his loss in the proxy battle for company control, but current management actually won by an "embarrassing" margin, the Globe and Mail says. Report

> In a recent interview at The Wharton School, Johnson & Johnson CEO Bill Weldon hinted that the company hasn't ruled out entering the generic-drugs market. Report

> A federal jury deliberated for a second day yesterday without reaching a verdict in the case of three Kentucky lawyers charged with defrauding clients of millions of dollars in a lawsuit over the diet drug fen-phen. Report

> San Diego-based Ardea BioSciences is reporting positive results from its Phase IIa proof-of-concept study for an experimental HIV therapy. Report

> Quark Pharmaceuticals says the FDA has approved its IND application for DGFi, an experimental siRNA drug for kidney transplant patients. Report

> Three years after plunking down $180 million to buy GlycArt, Roche says the sugar-related technology it acquired in the deal is demonstrating striking effectiveness enhancing experimental cancer therapies. Report

> The Global Alliance for Vaccines and Immunization, which is backed by a host of international health groups and the Gates Foundation, is preparing a huge new initiative to vaccinate millions of children in developing nations. Report

> The growing wealth seen in developing nations is spurring a big increase in the worldwide demand for vaccines, and Sanofi-Aventis says it will invest more than $6 billion over the next eight years in order to meet the projected demand. Report

And Finally... General anaesthesia may actually worsen post-operative pain. Report

Suggested Articles

Compared with the FDA "boxed warning," the EMA version puts a smaller restriction on the higher dose but broadens the cautionary language.

Shionogi's newest antibiotic Fetroja has now earned the FDA's approval, but will a mortality-rate warning scuttle the drug's chances?

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.